Michael E Dunn,Aaron Kithcart,Jee Hae Kim,Andre Jo-Hao Ho,Matthew C Franklin,Annabel Romero Hernandez,Jan de Hoon,Wouter Botermans,Jonathan Meyer,Ximei Jin,Dongqin Zhang,Justin Torello,Daniel Jasewicz,Vishal Kamat,Elena Garnova,Nina Liu,Michael Rosconi,Hao Pan,Satyajit Karnik,Michael E Burczynski,Wenjun Zheng,Ashique Rafique,Jonas B Nielsen,Tanima De,Niek Verweij,Anita Pandit,Adam Locke,Naga Chalasani,Olle Melander,Tae-Hwi Schwantes-An,Penn Medicine Biobank,Aris Baras,Luca A Lotta,Bret J Musser,Jason Mastaitis,Kishor B Devalaraja-Narashimha,Andrew J Rankin,Tammy Huang,Gary Herman,William Olson,Andrew J Murphy,George D Yancopoulos,Benjamin A Olenchock,Lori Morton,Daniel J Rader,Marylyn D Ritchie,JoEllen Weaver,Nawar Naseer,Afiya Poindexter,Khadijah Hu-Sain,Yi-An Ko,Meghan Livingstone,Fred Vadivieso,Stephanie DerOhannessian,Teo Tran,Julia Stephanowski,Monica Zielinski,Ned Haubein,Joseph Dunn,Anurag Verma,Colleen Morse Kripke,Marjorie Risman,Renae Judy,Shefali S Verma,Yuki Bradford,Scott Dudek,Theodore Drivas,Lance J Adams,Jackie Blank,Dale Bodian,Derek Boris,Adam Buchanan,David J Carey,Ryan D Colonie,F Daniel Davis,Dustin N Hartzel,Melissa Kelly,H Lester Kirchner,Joseph B Leader,David H Ledbetter,J Neil Manus,Christa L Martin,Raghu P Metpally,Michelle Meyer,Tooraj Mirshahi,Matthew Oetjens,Thomas Nate Person,Christopher Still,Natasha Strande,Amy Sturm,Jen Wagner,Marc Williams,Goncalo Abecasis,Michael Cantor,Giovanni Coppola,Andrew Deubler,Aris Economides,John D Overton,Jeffrey G Reid,Katherine Siminovitch,Alan Shuldiner,Christina Beechert,Caitlin Forsythe,Erin D Fuller,Zhenhua Gu,Michael Lattari,Alexander Lopez,Maria Sotiropoulos Padilla,Manasi Pradhan,Kia Manoochehri,Thomas D Schleicher,Louis Widom,Sarah E Wolf,Ricardo H Ulloa,Amelia Averitt,Nilanjana Banerjee,Dadong Li,Sameer Malhotra,Deepika Sharma,Jeffrey C Staples,Xiaodong Bai,Suganthi Balasubramanian,Suying Bao,Boris Boutkov,Siying Chen,Gisu Eom,Lukas Habegger,Alicia Hawes,Shareef Khalid,Olga Krasheninina,Rouel Lanche,Adam J Mansfield,Evan K Maxwell,George Mitra,Mona Nafde,Sean O'Keeffe,Max Orelus,Razvan Panea,Tommy Polanco,Ayesha Rasool,William Salerno,Kathie Sun,Joshua Backman,Amy Damask,Lee Dobbyn,Manuel Allen Revez Ferreira,Arkopravo Ghosh,Christopher Gillies,Lauren Gurski,Eric Jorgenson,Hyun Min Kang,Michael Kessler,Jack Kosmicki,Alexander Li,Nan Lin,Daren Liu,Jonathan Marchini,Anthony Marcketta,Joelle Mbatchou,Arden Moscati,Charles Paulding,Carlo Sidore,Eli Stahl,Kyoko Watanabe,Bin Ye,Blair Zhang,Andrey Ziyatdinov,Ariane Ayer,Aysegul Guvenek,George Hindy,Jan Freudenberg,Jonas Bovijn,Kavita Praveen,Manav Kapoor,Mary Haas,Moeen Riaz,Olukayode Sosina,Parsa Akbari,Priyanka Nakka,Sahar Gelfman,Sujit Gokhale,Veera Rajagopal,Gannie Tzoneva,Juan Rodriguez-Flores,Esteban Chen,Marcus B Jones,Michelle G LeBlanc,Jason Mighty,Lyndon J Mitnaul,Nirupama Nishtala,Nadia Rana,Jaimee Hernandez,Jennifer Rico Varela

Abstract:Heart failure is a leading cause of morbidity and mortality1,2. Elevated intracardiac pressures and myocyte stretch in heart failure trigger the release of counter-regulatory natriuretic peptides, which act through their receptor (NPR1) to affect vasodilation, diuresis and natriuresis, lowering venous pressures and relieving venous congestion3-8. Recombinant natriuretic peptide infusions were developed to treat heart failure but have been limited by a short duration of effect9,10. Here we report that in a human genetic analysis of over 700,000 individuals, lifelong exposure to coding variants of the NPR1 gene is associated with changes in blood pressure and risk of heart failure. We describe the development of REGN5381, an investigational monoclonal agonist antibody that targets the membrane-bound guanylate cyclase receptor NPR1. REGN5381, an allosteric agonist of NPR1, induces an active-like receptor conformation that results in haemodynamic effects preferentially on venous vasculature, including reductions in systolic blood pressure and venous pressure in animal models. In healthy human volunteers, REGN5381 produced the expected haemodynamic effects, reflecting reductions in venous pressures, without obvious changes in diuresis and natriuresis. These data support the development of REGN5381 for long-lasting and selective lowering of venous pressures that drive symptomatology in patients with heart failure.

Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases

Discovery of RXFP2 genetic association in resistant hypertensive men and RXFP2 antagonists for the treatment of resistant hypertension

High-Throughput Screening Campaign Identified a Potential Small Molecule RXFP3/4 Agonist

Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists

High-throughput screening campaign identifies a small molecule agonist of the relaxin family peptide receptor 4

Discovery of BAY 2413555, First Selective Positive Allosteric Modulator of the M2 Receptor to Restore Cardiac Autonomic Balance

Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone

Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist

Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF)

Design, Synthesis, and Evaluation of the Selective and Orally Active LSD1 Inhibitor with the Potential of Treating Heart Failure

Engineering and Characterization of a Long Half-Life Relaxin Receptor RXFP1 Agonist

Daily Subcutaneous injections of Relaxin is a therapy for heart failure with preserved ejection fraction